Friday, 31 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Economy > Biogen Inc. (BIIB): A Bull Case Theory
Economy

Biogen Inc. (BIIB): A Bull Case Theory

Last updated: September 30, 2025 2:20 pm
Share
Biogen Inc. (BIIB): A Bull Case Theory
SHARE

Recently, a compelling bullish thesis on Biogen Inc. was published on Investing With Purpose’s Substack. This article delves into the key points of the bullish argument surrounding BIIB. As of September 18th, Biogen’s shares were trading at $143.81, with trailing and forward P/E ratios standing at 13.86 and 9.04 respectively, according to Yahoo Finance.

Bullish on Biogen

Image Source: create jobs 51/Shutterstock.com

As Biogen (BIIB) approaches its Q2 earnings report on July 31, investors are particularly interested in how the rollout of its Alzheimer’s drug, lecanemab, will impact the company’s future, alongside the stability of its multiple sclerosis (MS) treatment segment. Despite trading at a lower valuation than its peers, even with a robust net-cash balance sheet and an advancing pipeline, BIIB appears to be undervalued ahead of potential catalysts. The consensus forecast expects revenue around $2.65 billion, reflecting a 3% year-over-year decline, along with an EPS estimate of $3.20, suggesting a possible upside due to premium pricing for lecanemab. Recent data indicated a 25% reduction in hospitalizations, which has fueled hope for an expanded FDA label and greater adoption of the drug.

In addition to Alzheimer’s advancements, Biogen’s pipeline also includes promising SMA follow-ups and therapies targeting synuclein for Parkinson’s, presenting investors with multiple potential revenue streams through 2027. The company’s strong balance sheet—boasting $10 billion in cash against $6 billion in debt—affords significant flexibility for research and development, share buybacks, or potential mergers and acquisitions. The stock has shown resilience, bouncing off the $125 support level and currently resting just beneath the 100-day simple moving average (SMA) of $129. Resistance levels are found between $132 and $136, with the Relative Strength Index (RSI) positioned neutrally around 50 and a flat Moving Average Convergence Divergence (MACD), setting the stage for a substantial post-earnings movement.

See also  Retail investors ditch buy-the-dip mentality during market correction

Potential scenarios indicate an upside target between $138 and $145 if earnings surpass expectations, or a downside to $118 to $122 should MS sales disappoint. For investors considering entry, a starting position around $128 to $130 is advisable, allowing for scaling into strength beyond $132 or adding on any pullbacks, while maintaining tight stops to control risk. The upcoming Q2 results could very well serve as the catalyst needed to unlock Biogen’s current undervaluation, with positive developments in the Alzheimer’s space and resilient revenues offering an appealing risk/reward profile.

In a similar context, we previously discussed a bullish thesis regarding Gilead Sciences, Inc. (GILD) presented by Disruptive Analytics in February 2025. This analysis pointed out immediate revenue challenges due to the Inflation Reduction Act, a strong U.S. dollar, and the decline in COVID-related hospitalizations, while also emphasizing Gilead’s prudent cost management and optimistic outlook for 2026. Since that coverage, GILD has seen an approximate appreciation of 9.16%. The bullish perspective on Gilead endures; however, Investing With Purpose focuses on Biogen’s long-term undervaluation, the catalyst from Alzheimer’s drugs, and the favorable immediate trading setup.

This rewritten article maintains the structure and key points of the original while ensuring that the content is unique and suitable for a WordPress platform.

TAGGED:BIIBBiogenbullcaseTheory
Share This Article
Twitter Email Copy Link Print
Previous Article Homeless stranger rapes woman, 36, inside NYC building – terrified victim offers him money to stop: DA Homeless stranger rapes woman, 36, inside NYC building – terrified victim offers him money to stop: DA
Next Article Prosecutors Urge Judge to Sentence Diddy to More Than 11 Years in Prison Prosecutors Urge Judge to Sentence Diddy to More Than 11 Years in Prison
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

USMNT roster: Christian Pulisic in, Weston McKennie out as USA soccer nears Mauricio Pochettino hire

The U.S. men's national team is gearing up for a return to action with friendlies…

September 1, 2024

House Democrat Trashes Trump’s Cabinet Picks With Brutal Made-For-TV Dig

In a scathing speech on the House floor, Rep. Jim McGovern (D-Mass.) criticized Donald Trump's…

December 5, 2024

‘Breaking Bad’ Home Owner Wants It to Be Turned Into Museum, Sticks by $4M Price

'Breaking Bad' Owner Sticking By $4M Price tag ... You Could Cook Up a Museum…

August 12, 2025

Blake Lively Addresses Justin Baldoni Drama at Time 100 Gala

Blake Lively made a powerful statement at the Time 100 Gala in New York City,…

April 25, 2025

Oil Industry Braces for Glut and Investor Demands

The oil and gas sector is poised to face a challenging year as it strives…

September 28, 2025

You Might Also Like

Is This The Best ETF to Invest In Ahead of Potential AI Bubble Burst?
Economy

Is This The Best ETF to Invest In Ahead of Potential AI Bubble Burst?

October 31, 2025
Alphabet hikes capex again after earnings beat on strong ad, cloud demand
Economy

Alphabet hikes capex again after earnings beat on strong ad, cloud demand

October 31, 2025
What is a merchant bank?
Economy

What is a merchant bank?

October 30, 2025
NASA Refutes Kim Kardashian’s Fake Moon Landing Conspiracy Theory
Entertainment

NASA Refutes Kim Kardashian’s Fake Moon Landing Conspiracy Theory

October 30, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?